Tscan therapeutics to participate in the lifesci 2nd annual genetic medicines symposium

Waltham, mass., june 22, 2022 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t-cell receptor (tcr) engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced that management will participate in a virtual fireside chat at the lifesci 2nd annual genetic medicines symposium on tuesday, june 28, 2022, at 9:00 a.m. et.
TCRX Ratings Summary
TCRX Quant Ranking